The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Dublin, Ireland
1-10 Employees
2019
Our Mission“To pioneer innovation through dedication in developing polymer based gene therapy transformative medicines“. Branca Bunús Ltd is a UCD start-up gene therapy company founded by Prof Wenxin Wang. Branca Bunús Ltd is dedicated to developing and commercialising gene therapy products for the treatments of patients suffering from genetic disorders around the world. Our patented gene therapy platform technology centres on a non-viral polymer based delivery approach. Our initial focus is the development of a CRISPR gene editing therapy delivered using our unique non-viral polymer platform technology for the treatment of the rare skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). Branca Bunús Ltd is dedicated to developing and commercialising polymer based gene therapeutics for patients suffering from genetic disorders around the world. Branca Bunús Ltd is a UCD start-up gene therapy company founded by Prof.
+
Featured
CRISPR Gene Editing:
... CRISPR Gene Editing: ...
Stevenage, United Kingdom
11-50 Employees
Laverock's differentiated technology allows generation of products with improved efficacy, safety and accessibility, overcoming many of the limitations with existing approaches. These next-generation products are able to deliver directed, responsive activities ensuring favourable on- and off-target profiles.
+
Featured
Programmable Cell Therapies, CRISPR Gene Editing | Laverock Therapeutics
... Programmable Cell Therapies, CRISPR Gene Editing | Laverock ...
Lyon, France
51-100 Employees
1999
The current genOway management committee is composed of six members: Alexandre Fraichard, Benjamin Bruneau, Cyrielle Chabrier, Florent Pons, Yacine Cherifi and Kader Thiam. We are the only company to invest heavily in this consulting activity, and each project feasibility analysis represents seven days of full-time equivalent activity of experts in bioinformatics, gene targeting, molecular biology, and cell biology. At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. Founded in 1999 by a four-member team around founder Alexandre Fraichard, genOway now has risen to become a leader in the field of customized, genetically modified (GM) mouse, rat and cell model creation. We have built a unique license portfolio for all technologies used, including exclusive licenses, which we are allowed to sublicense. Furthermore, our customers retain ownership of the deliverables and can patent the model developed. This provides you with cohorts ready for experimentation.
+
Featured
CRISPR/Cas9 Gene Editing
... CRISPR/Cas9 Gene Editing ...
Beijing, China
11-50 Employees
2000
We provide optimized solutions for life science research. We are honored to create value for our customers and facilitate the development of science. Our high quality products are trusted by researchers and scientists in top universities and institutes. Our support personnel is all experts with an average of more than 10 years of working experience. Thousands of papers have been published in the world's top academic journals with our products.
+
Featured
SD DNA Polymerase (1,000U)
... CRISPR Gene Editing ...
Hayward, United States
11-50 Employees
2011
At DiaCarta, our mission is to improve the lives of cancer patients through innovative precision diagnostics. We are committed to providing accurate, reliable, and affordable diagnostics that help physicians make informed treatment decisions. Patient-Centric operations: Our mission is to provide innovative and affordable solutions for cancer patient management, and we prioritize the needs of patients and their families in everything we do. Innovation: We are committed to advancing precision diagnostics and improving patient outcomes through cutting-edge research and development. Continuous Improvement: We are dedicated to ongoing improvement and innovation, and we invest in the development of our team, our products, and our infrastructure to better serve our customers and achieve our mission. We are committed to designing and manufacturing products with the good of the patient in mind. DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage. DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience.
+
Featured
CRISPR-Quest Gene Editing Test
... CRISPR-Quest Gene Editing Test | DiaCarta, Inc. ...
Cambridge, United States
101-250 Employees
2013
We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.
+
Featured
CRISPR Therapeutics Announces European Patent for CRISPR/Cas… | CRISPR
... CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing ...
Rishon LeZion, Israel
11-50 Employees
1959
YEDA Technology Transfer from the Weizmann Institute of Science. Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. The innovation ecosystem comprises of three separate but interrelated units within the Institute.
+
Featured
Pharmaceuticals Research Tools Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930)
... Pharmaceuticals Research Tools Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930) ...
Cambridge, United States
51-100 Employees
2017
Our vision is to create life-long cures through gene-based editing – one letter at a time. We are located at: 238 Main Street, Cambridge, MA 02142. We are located at: 10 Davis Drive, Durham, North Carolina 27709. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases. Giuseppe Ciaramella is the President of Beam Therapeutics. Gopi Shanker is the Chief Scientific Officer of Beam Therapeutics. O’Connor holds a bachelor’s degree from Providence College. Brian Riley, an experienced leader in operations, quality and manufacturing, is Chief Manufacturing Officer at Beam.
+
Featured
Our Story | Beam Therapeutics
... Keith Joung, scientific pioneers in CRISPR gene editing. Bringing together their passion, expertise, and determination to develop lifelong cures for patients suffering from serious diseases. ...
San Francisco, United States
11-50 Employees
1998
Created in a first of its kind partnership with the US Space Force, Astro provides a complete UX Tool Kit for mission critical applications. Thermo Fisher Scientific is the world leader in scientific and medical devices. They help their customers accelerate life sciences research, solve complex analytical challenges, and increase productivity in their laboratories. CyDesign provides a physics-based modeling system that allows engineers to quickly assess design options against requirements during the conceptual design stage.
+
Featured
GENOME APP | Inscripta - Rocket Communications
... Revolutionized and accelerated the CRISPR gene editing process with a ...
London, United Kingdom
11-50 Employees
1960
With over 2,800 members worldwide, we are the largest UK haematology organisation and the only society to cover all aspects of the specialty. LeadingBridging the gap between research and practice, our guidelines raise the standards of clinical and patient care. The chief ways that BSH acts on its mission are:. We bring committed volunteers together to support our purpose to champion and strengthen haematology practice.
+
Featured
CRISPR gene editing library identifies new immune regulators
... Scientists have created the first retroviral CRISPR-Cas9 gene editing library to examine the regulation of mouse T cells, it was announced last week. Although it is known that T helper type 2 cells (Th2) release specific chemicals to tell the body to kill invaders, it is unclear ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for CRISPR Gene Editing
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 24 |
| Amount of suitable service providers | 13 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1959 |
| Youngest suiting company | 2019 |
CRISPR gene editing, a groundbreaking technology in the realm of genetics, stands for Clustered Regularly Interspaced Short Palindromic Repeats. This method utilizes a protein known as Cas9, which functions as a pair of molecular scissors, capable of making precise cuts in DNA. Guided by a specially designed RNA sequence that matches the target DNA sequence, CRISPR-Cas9 can add, remove, or alter specific genetic material with unprecedented accuracy. This precision allows scientists to study genes' functions by observing how changes in DNA affect cellular processes, offering insights into the genetic basis of diseases. Beyond research, CRISPR has immense therapeutic potential, with applications ranging from correcting genetic defects to treating infectious diseases and even preventing the spread of pathogens in crops, thereby revolutionizing both medicine and agriculture. Its ability to edit genes quickly, cheaply, and with high precision has not only accelerated genetic research but has also sparked ethical debates, particularly concerning germline editing which affects future generations. Despite these concerns, CRISPR's role in advancing our understanding and manipulation of the genome is unparalleled, positioning it at the forefront of genetic engineering technologies.
1. Precision
CRISPR gene editing offers unparalleled precision in modifying genetic sequences, allowing scientists to target and edit genes with high specificity. This accuracy minimizes off-target effects, a common issue with earlier gene-editing technologies, enhancing the safety and effectiveness of genetic modifications.
2. Efficiency and Speed
One of the most significant advantages of CRISPR is its efficiency. This technology enables the editing of multiple genes simultaneously, a feat that was time-consuming and complex with previous methods. Additionally, CRISPR's processes are faster, significantly reducing the time from research to application, which is crucial in fields like medicine and agriculture.
3. Accessibility
Compared to its predecessors, CRISPR technology is more accessible to researchers worldwide due to its relatively low cost and ease of use. This democratization of gene editing means that more scientists can contribute to genetic research, accelerating advancements in genetic therapies, crop improvement, and more.
4. Versatility
CRISPR's flexibility allows it to be applied across various organisms, including humans, plants, and microorganisms. This versatility opens up a wide range of possibilities for genetic research and applications, from treating hereditary diseases to enhancing crop resilience against climate change.
While evaluating the different suppliers make sure to check the following criteria:
1. Experience and Expertise
Ensure the supplier has a proven track record in CRISPR technology and a deep understanding of gene editing complexities.
2. Quality Control Measures
Assess the quality control protocols in place to ensure high-fidelity gene editing outcomes.
3. Customization Capabilities
Verify if the supplier can tailor their CRISPR solutions to meet specific project requirements.
4. Support and Consultation Services
Evaluate the level of technical support and consultation provided to navigate potential challenges during the project.
5. Turnaround Time and Scalability
Consider the supplier's ability to deliver results within your project timeline and their capacity for scaling up operations if needed.
6. Compliance and Ethical Standards
Check for adherence to international regulatory standards and ethical guidelines in genetic engineering.
7. Cost-Effectiveness
Balance between quality of service and cost, ensuring the supplier offers competitive pricing without compromising on the quality of CRISPR gene editing services.
CRISPR gene editing technology has revolutionized various industries, providing innovative solutions to long-standing challenges. In agriculture, companies leverage CRISPR to enhance crop resilience against pests and environmental stress, thereby increasing yield and sustainability. Through precise genetic modifications, crops can be made more resistant to diseases and adverse weather conditions, a critical advancement for ensuring global food security. In the healthcare sector, CRISPR has opened new avenues for personalized medicine and treatments. Pharmaceutical and biotechnology firms are developing gene therapies targeting specific genetic disorders, offering hope for conditions previously deemed untreatable. By correcting gene mutations at their source, these therapies promise to improve patient outcomes significantly, reducing the overall burden of genetic diseases. The biomanufacturing industry also benefits from CRISPR technology by engineering microorganisms for the production of pharmaceuticals, biofuels, and specialty chemicals. These genetically modified organisms can produce high-value products more efficiently and sustainably, reducing reliance on traditional, resource-intensive processes. This application of CRISPR not only enhances productivity but also contributes to environmental sustainability by promoting cleaner manufacturing practices. Through these diverse applications, CRISPR gene editing is facilitating groundbreaking advancements across sectors, demonstrating its versatility and potential to address complex challenges in innovative ways.
CRISPR gene editing, a groundbreaking technique in genetic engineering, is situated at various Technology Readiness Levels (TRLs) depending on its application, with the most advanced being around TRL 6-7 in medical research and therapeutic development. This classification stems from successful demonstrations of its efficacy in controlled environments, such as laboratory settings, where it has been utilized to edit the DNA of human cells with high precision. The technique has shown promise in treating genetic disorders by correcting mutations at their source, a revolutionary approach that has already led to clinical trials for conditions like sickle cell anemia and beta-thalassemia. The reason CRISPR is not at a higher TRL, despite its potential, lies in the technical challenges and ethical considerations that accompany its application to human genetics. Issues such as off-target effects, where unintended parts of the genome are edited, and the long-term impacts of gene editing on patients and their descendants require extensive research to fully understand and mitigate. Additionally, the delivery mechanisms for CRISPR components into human cells in vivo are still being optimized for efficiency and safety. These technical hurdles must be overcome before CRISPR can advance to higher TRLs and see more widespread use in treating genetic diseases.
In the Short-Term, CRISPR gene editing is expected to see significant advancements in precision and efficiency. Researchers are working on refining the technology to minimize off-target effects, which will enhance its safety profile for clinical applications. The development of more sophisticated CRISPR systems, such as base and prime editing, aims to enable precise single nucleotide changes without making double-strand breaks, reducing the risk of unintended mutations. These improvements are poised to facilitate the transition of CRISPR from research labs into therapeutic settings, particularly for treating genetic disorders. The Mid-Term outlook for CRISPR gene editing involves its expansion into complex genetic diseases and agricultural improvements. As the technology becomes more refined, it will be employed to tackle polygenic diseases, where multiple genes are involved. This phase will also witness the rise of CRISPR in enhancing crop resilience, yield, and nutritional value, addressing food security issues. The ethical and regulatory landscape will evolve to keep pace with these advancements, focusing on ensuring safe and equitable access to CRISPR technologies across diverse sectors. Looking into the Long-Term, CRISPR gene editing is anticipated to revolutionize personalized medicine and biodiversity conservation. The technology's integration with artificial intelligence will enable the design of highly personalized therapeutic interventions based on an individual's genetic makeup, ushering in a new era of precision medicine. Additionally, CRISPR could play a crucial role in conserving endangered species and restoring biodiversity by genetically modifying organisms to enhance their survival rates. These ambitious applications underscore CRISPR's potential to address some of the most pressing challenges facing humanity and the planet.
